Drug Profile
Research programme: DNA vaccines - Inovio/National Cancer Institute
Latest Information Update: 30 Apr 2012
Price :
$50
*
At a glance
- Originator Genetronics Inc
- Developer Inovio Pharmaceuticals; National Cancer Institute (USA)
- Class AIDS vaccines; Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; HIV infections
Most Recent Events
- 30 Apr 2012 No development reported - Preclinical for Cancer in USA (IM)
- 30 Apr 2012 No development reported - Preclinical for HIV infections in USA (IM)
- 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals